Gross Margin % is calculated as gross profit divided by its revenue. Biotest AG's Gross Profit for the
three
months ended in Mar. 2025 was €14.1 Mil. Biotest AG's Revenue for the
three
months ended in Mar. 2025 was €124.2 Mil. Therefore, Biotest AG's Gross Margin % for the quarter that ended in Mar. 2025 was 11.35%.
The historical rank and industry rank for Biotest AG's Gross Margin % or its related term are showing as below:
HAM:BIO's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Biotest AG had a gross margin of 11.35% for the quarter that ended in Mar. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Biotest AG was 0.00% per year.
Biotest AG (HAM:BIO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biotest AG had a gross margin of 11.35% for the quarter that ended in Mar. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biotest AG Gross Margin % Related Terms
Biotest AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for Biotest AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BIO vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Biotest AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotest AG Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotest AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Biotest AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biotest AG (HAM:BIO) has a Gross Margin % of 11.35% as of Mar. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Biotest AG and its competitors.
Is Biotest AG's Gross Margin % too high?
Biotest AG's current Gross Margin % is 11.35%. The Biotechnology industry median Gross Margin % is 60.91. Biotest AG's value of 11.35% is 81.4% below this industry median. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Gross Margin % compare to VRTX and REGN?
Biotest AG's Gross Margin % of 11.35% can be compared against companies in the Biotechnology industry. The industry median Gross Margin % is 60.91. Biotest AG's value of 11.35% is 81.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotest AG's current Gross Margin % of 11.35% is 81.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Biotest AG and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotest AG's current Gross Margin % is 11.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Gross Margin % of 11.35%. The current Gross Margin % is 11.35% and 81.4% below the Biotechnology industry median of 60.91. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Gross Margin % is 11.35% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score
Get the complete analysis for HAM:BIO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BIO has been successfully added to your 
